Cancer Genetics Submits Tests to NIH Genetic Testing Registry | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics this week said it had submitted information about three genomic and prognostic tests to the NIH's Genetic Testing Registry.

The GTR listed tests include FHACT, an HPV-associated cervical cancer test that gauges genomic abnormalities linked to disease progression; UroGenRA-Kidney, a test that can diagnose and subtype renal cell carcinoma; and MatBA, a panel for mature B-cell neoplasms, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.